Clinical Trial Update: Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors [Phase 3]

View source ↗

Summary

Phase 3 study of recombinant coagulation factor VIIa in congenital hemophilia A or B patients with inhibitors; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Coagulation FVIIa (Recombinant) (recombinant coagulation factor VIIa)

Snippet

Sponsor: rEVO Biologics | Conditions: Hemophilia A With Inhibitors, Hemophilia B With Inhibitors | Phase 3 | Status: COMPLETED | Results posted: 2017-06-14